# Trans-catheter Arterial Embolization Combined With p53 Gene Therapy for Treatment of Advanced Hepatocellular Carcinoma

> **NCT02509169** · PHASE2 · UNKNOWN · sponsor: **Shenzhen SiBiono GeneTech Co.,Ltd** · enrollment: 60 (estimated)

## Conditions studied

- Advanced Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** TAE plus P53 gene
- **OTHER:** TAE

## Key facts

- **NCT ID:** NCT02509169
- **Lead sponsor:** Shenzhen SiBiono GeneTech Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-10
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2015-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02509169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02509169, "Trans-catheter Arterial Embolization Combined With p53 Gene Therapy for Treatment of Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02509169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*